Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142082 | 0.92 | GPR119 (0.49) | GPR119DDB1CRBNF11WNT3A | |
| SCHEMBL10179975 | 0.90 | GPR119 (0.47) | GPR119DDB1CRBNF11TLR7 | |
| SCHEMBL14142049 | 0.90 | GPR119 (0.49) | GPR119F11 | |
| SCHEMBL12544773 | 0.90 | GPR119 (0.39) | GPR119TLR7KCNH2 | |
| SCHEMBL10179669 | 0.89 | KCNJ1 (0.38) | GPR119F11KCNH2 | |
| SCHEMBL10203528 | 0.87 | GPR119 (0.52) | GPR119DDB1CRBNF11WNT3A | |
| SCHEMBL10203527 | 0.86 | DDB1 (0.44) | GPR119DDB1CRBNWNT3ATLR7 | |
| SCHEMBL10179223 | 0.83 | GPR119 (0.48) | GPR119DDB1CRBN | |
| SCHEMBL10203530 | 0.83 | DDB1 (0.41) | GPR119DDB1CRBNWNT3ATLR7 | |
| SCHEMBL14142236 | 0.81 | GPR119 (0.40) | GPR119F11TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | GPR119 1/4885DDB1 4538/4885CRBN 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.